Current microbiological testing approaches and documented infections at febrile neutropenia onset in patients with hematologic malignancies

被引:0
|
作者
Mariana, Chumbita [1 ]
Olivier, Peyrony [1 ,2 ]
Christian, Teijon-Lumbreras [1 ]
Patricia, Monzo-Gallo [1 ]
Francesco, Aiello Tommaso [1 ]
Antonio, Gallardo-Pizarro [1 ]
Emmanuelle, Gras [1 ,3 ]
Pedro, Puerta-Alcalde [1 ]
Espasa, Mateu [4 ]
Carmen, Martinez [5 ]
Andrea, Rivero [5 ]
Climent, Casals-Pascual [4 ]
Alex, Soriano [1 ,6 ]
Carolina, Garcia-Vidal [1 ,6 ]
机构
[1] Univ Barcelona, Hosp Clin Barcelona IDIBAPS, Dept Infect Dis, Barcelona, Spain
[2] Hop St Louis, AP HP, Emergency Dept, Paris, France
[3] Sorbonne Univ, Inst Pierre Louis Epidemiol & Sante Publ, INSERM, Paris, France
[4] Hosp Clin Barcelona, Dept Microbiol, Barcelona, Spain
[5] Hosp Clin Barcelona, Hematol Dept, Barcelona, Spain
[6] Ctr Biomed Res Infect Dis Network CIBER, Barcelona, Spain
关键词
Febrile neutropenia; Epidemiology; Bacteremia; Hematologic patients; RISK; STEWARDSHIP; DISEASES; SPECTRUM;
D O I
10.1016/j.ijid.2024.107183
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Objectives: This study aims to identify infection etiology in febrile neutropenia (FN) is vital. This study explores different microbiological approaches and their impact on diagnosing infections in patients with hematologic malignancies and FN. Methods: This is a retrospective analysis conducted at the Hospital Clinic of Barcelona details microbiological testing strategies used to diagnose infections at FN onset between January 2020 and July 2022. Results: A total of 4520 microbiological tests were ordered in 462 FN episodes, achieving a 10% test positivity rate, with 200 (43.3%) episodes showing microbiological documentation of infection. Blood cultures (40.4%), non-culture blood tests (21.2%), and respiratory tract samples (16.2%) were the most requested. Blood cultures exhibited the highest (16.9%) test positivity rates, whereas non-culture blood tests showed the lowest (3.3%). Bacterial infections were present in 149 of 462 (32.3%) FN episodes. Viral infections (66 of 462, 14.3%)-notably, respiratory viruses-were also frequent. Mortality rate at 60 days was 9.1%; documented infections were associated with a higher risk (15%). Conclusions: In the current landscape of antimicrobial diagnostics, our findings revealed the highest reported rate of microbiologically documented infections at FN onset. Bacterial infections are common; however, our data reiterate the significance of viral infections in causing fever. Optimizing FN management during respiratory viral infections remains a challenge for antimicrobial de-escalation. The low positivity rates observed in certain diagnostic tests emphasize the need for cost-effective diagnostic stewardship.
引用
收藏
页数:7
相关论文
共 50 条
  • [1] Febrile Neutropenia in Hematologic Malignancies
    Keng, Michael K.
    Sekeres, Mikkael A.
    [J]. CURRENT HEMATOLOGIC MALIGNANCY REPORTS, 2013, 8 (04) : 370 - 378
  • [2] Febrile Neutropenia in Hematologic Malignancies
    Michael K. Keng
    Mikkael A. Sekeres
    [J]. Current Hematologic Malignancy Reports, 2013, 8 : 370 - 378
  • [3] Approach to febrile neutropenia in patients undergoing treatments for hematologic malignancies
    Stohs, Erica J.
    Abbas, Anum
    Freifeld, Alison
    [J]. TRANSPLANT INFECTIOUS DISEASE, 2024, 26 (02)
  • [4] FACTORS AFFECTING THE OUTCOME OF FEBRILE NEUTROPENIA IN PATIENTS WITH HEMATOLOGIC MALIGNANCIES
    Zawam, H.
    Edesa, W.
    Salama, R.
    Gaber, M.
    Sherief, M.
    Naseef, C.
    Ezzat, N.
    [J]. HAEMATOLOGICA, 2015, 100 : 475 - 475
  • [5] Cefpirome as empirical treatment for febrile neutropenia in patients with hematologic malignancies
    Timmers, Gert Jan
    van Vuurden, Dannis G.
    Swart, Eleonora L.
    Simoons-Smit, Alberdina M.
    Huijgens, Peter C.
    [J]. HAEMATOLOGICA, 2005, 90 (07) : 1005 - 1006
  • [6] Impact of fluoroquinolone prophylaxis on documented infections in patients with febrile neutropenia
    Przybylski, Daniel J.
    Reeves, David J.
    [J]. INFECTIOUS DISEASES, 2018, 50 (05) : 395 - 398
  • [7] CURRENT APPROACH TO TREATMENT OF FEBRILE NEUTROPENIA IN HEMATOLOGIC PATIENTS
    Busca, A.
    De Rosa, F. G.
    [J]. HAEMATOLOGICA, 2015, 100 : 187 - 189
  • [8] Clinical and microbiological effects of biapenem in febrile neutropenic patients with hematologic malignancies
    Isobe, Yasushi
    Kanemitsu, Naoko
    Yahata, Yuriko
    Masuda, Azuchi
    Tsukune, Yutaka
    Sugimoto, Koichi
    [J]. SCANDINAVIAN JOURNAL OF INFECTIOUS DISEASES, 2009, 41 (03) : 237 - 239
  • [9] Utilization of cefepime therapeutic drug monitoring in febrile neutropenia patients with hematologic malignancies
    Lodl, Emma F.
    Alshaer, Mohammad H.
    Adams, C. Brooke
    Richards, Ashley
    Peloquin, Charles
    Venugopalan, Veena
    [J]. JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023,
  • [10] Prospective Study Of An Emergency Department Febrile Neutropenia Pathway In Patients With Hematologic Malignancies
    Keng, Michael K.
    Thallner, Elaine
    Elson, Paul
    Zayac, Christine
    Sekeres, Jennifer
    Wenzell, Candice M.
    Gallagher, Erika M.
    Weber, Catherine M.
    Earl, Marc A.
    Mukherjee, Sudipto
    Seastone, David J.
    Pohlman, Brad
    Cober, Eric
    Rodgers, Beth
    Foster, Virginia B.
    Yuhas, Joy
    Kalaycio, Matt
    Bolwell, Brian J.
    Sekeres, Mikkael A.
    [J]. BLOOD, 2013, 122 (21)